Published in Cardiol Ther on October 05, 2016
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med (2011) 1.82
Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost (2009) 1.58
Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol (2010) 1.31
Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J (2012) 1.27
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol (2012) 1.24
Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes (2008) 1.11
Reversal of anticoagulants: an overview of current developments. Thromb Haemost (2015) 1.05
Natural history of functional gastrointestinal disorders: comparison of two longitudinal population-based studies. Dig Liver Dis (2011) 0.84
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. Europace (2016) 0.83
Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation. Curr Cardiol Rev (2014) 0.80